Preclinical in vivo-models to investigate HIPEC : current methodologies and challenges
- Author
- Roxan F. C. P. A. Helderman, Daan R. Löke, Pieter J. Tanis, Jurriaan B. Tuynman, Wim Ceelen (UGent) , Ignace H. de Hingh, Kurt van der Speeten, Nicolaas A. P. Franken, Arlene L. Oei, H. Petra Kok and Johannes Crezee
- Organization
- Abstract
- Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.
- Keywords
- Cancer Research, Oncology, peritoneal carcinomatosis, peritoneal metastasis, cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY, COLORECTAL PERITONEAL CARCINOMATOSIS, RECURRENT OVARIAN-CANCER, CYTOREDUCTIVE SURGERY, TISSUE DISTRIBUTION, SYSTEMIC CHEMOTHERAPY, CHEMOPERFUSION HIPEC, COLONIC ANASTOMOSIS, XENOGRAFT MODEL, GASTRIC-CANCER
Downloads
-
published.pdf
- full text (Published version)
- |
- open access
- |
- |
- 4.05 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8715776
- MLA
- Helderman, Roxan F. C. P. A., et al. “Preclinical in Vivo-Models to Investigate HIPEC : Current Methodologies and Challenges.” CANCERS, vol. 13, no. 14, 2021, doi:10.3390/cancers13143430.
- APA
- Helderman, R. F. C. P. A., Löke, D. R., Tanis, P. J., Tuynman, J. B., Ceelen, W., de Hingh, I. H., … Crezee, J. (2021). Preclinical in vivo-models to investigate HIPEC : current methodologies and challenges. CANCERS, 13(14). https://doi.org/10.3390/cancers13143430
- Chicago author-date
- Helderman, Roxan F. C. P. A., Daan R. Löke, Pieter J. Tanis, Jurriaan B. Tuynman, Wim Ceelen, Ignace H. de Hingh, Kurt van der Speeten, et al. 2021. “Preclinical in Vivo-Models to Investigate HIPEC : Current Methodologies and Challenges.” CANCERS 13 (14). https://doi.org/10.3390/cancers13143430.
- Chicago author-date (all authors)
- Helderman, Roxan F. C. P. A., Daan R. Löke, Pieter J. Tanis, Jurriaan B. Tuynman, Wim Ceelen, Ignace H. de Hingh, Kurt van der Speeten, Nicolaas A. P. Franken, Arlene L. Oei, H. Petra Kok, and Johannes Crezee. 2021. “Preclinical in Vivo-Models to Investigate HIPEC : Current Methodologies and Challenges.” CANCERS 13 (14). doi:10.3390/cancers13143430.
- Vancouver
- 1.Helderman RFCPA, Löke DR, Tanis PJ, Tuynman JB, Ceelen W, de Hingh IH, et al. Preclinical in vivo-models to investigate HIPEC : current methodologies and challenges. CANCERS. 2021;13(14).
- IEEE
- [1]R. F. C. P. A. Helderman et al., “Preclinical in vivo-models to investigate HIPEC : current methodologies and challenges,” CANCERS, vol. 13, no. 14, 2021.
@article{8715776, abstract = {{Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.}}, articleno = {{3430}}, author = {{Helderman, Roxan F. C. P. A. and Löke, Daan R. and Tanis, Pieter J. and Tuynman, Jurriaan B. and Ceelen, Wim and de Hingh, Ignace H. and van der Speeten, Kurt and Franken, Nicolaas A. P. and Oei, Arlene L. and Kok, H. Petra and Crezee, Johannes}}, issn = {{2072-6694}}, journal = {{CANCERS}}, keywords = {{Cancer Research,Oncology,peritoneal carcinomatosis,peritoneal metastasis,cytoreductive surgery (CRS),hyperthermic intraperitoneal chemotherapy (HIPEC),HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY,COLORECTAL PERITONEAL CARCINOMATOSIS,RECURRENT OVARIAN-CANCER,CYTOREDUCTIVE SURGERY,TISSUE DISTRIBUTION,SYSTEMIC CHEMOTHERAPY,CHEMOPERFUSION HIPEC,COLONIC ANASTOMOSIS,XENOGRAFT MODEL,GASTRIC-CANCER}}, language = {{eng}}, number = {{14}}, pages = {{24}}, title = {{Preclinical in vivo-models to investigate HIPEC : current methodologies and challenges}}, url = {{http://doi.org/10.3390/cancers13143430}}, volume = {{13}}, year = {{2021}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: